Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer

The current study aimed to investigate baseline anemia in patients with stage IV non-small cell lung cancer (NSCLC) and its relationship with clinicopathological features and prognosis. The clinical data of 4,874 patients with stage IV NSCLC were analyzed. The incidence of baseline anemia was observed. The relationship between baseline anemia and clinicopathological features was analyzed. Kaplan-Meier method and multivariate COX regression model were used to analyze the relationship of baseline anemia and prognosis of patients with NSCLC. Anemia classification was based on the criteria established by the National Cancer Institute (NCI). The mean hemoglobin (Hb) was 123.32±20.31 g/l in patients with stage IV NSCLC. The prevalence of baseline anemia was 32.09%, among which 19.08, 10.79, 1.91 and 0.31% had mild, moderate, severe, and life-threatening anemia, respectively. The prevalence of baseline anemia was higher in patients who were >60 years old, male, had smoking history, exhibited squamous cell carcinoma and bone metastasis, and the difference was statistically significant. Univariate analysis indicated that patients without anemia had longer overall survival (OS) compared with patients with baseline anemia (median OS: 28.0 months vs. 17.4 months, P<0.001). As the grade of anemia rises, it was indicated that OS became shorter. Patients with anemia grade 0 had the longest OS (median OS: 28.0 months), followed by patients with anemia grades 1 and 2 (median OS: 17.5 months). The patients with anemia grades 3 and 4 had the shortest OS (median OS: 8.6 months; P<0.001). Multivariate analysis demonstrated that baseline anemia and anemia grade were independent prognostic factors in patients with stage IV NSCLC. In conclusion, baseline anemia and anemia grade are independent prognostic factors in patients with stage IV NSCLC.

[1]  G. Rossi,et al.  Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. , 2019, Critical reviews in oncology/hematology.

[2]  Yang Liu,et al.  Preoperative anemia as a prognostic factor in patients with lung cancer: a systematic review and meta-analysis of epidemiological studies , 2019, Journal of Cancer.

[3]  F W MULSOW,et al.  Cancer incidence and mortality , 2019, Health at a Glance: Europe.

[4]  J. Pantarotto,et al.  Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT) , 2019, Clinical and translational radiation oncology.

[5]  S. Hahn,et al.  Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer. , 2018, Lung cancer.

[6]  Y. Zhang,et al.  Pre-treatment hemoglobin levels are an independent prognostic factor in patients with non-small cell lung cancer. , 2018, Molecular and clinical oncology.

[7]  Jie He,et al.  Cancer incidence and mortality in China, 2014. , 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[8]  M. Zhou,et al.  Trend analysis of cancer incidence and mortality in China , 2017, Science China Life Sciences.

[9]  K. Batra,et al.  Revisions to the Tumor, Node, Metastasis staging of lung cancer (8th edition): Rationale, radiologic findings and clinical implications , 2017, World journal of radiology.

[10]  A. Giglio,et al.  Epidemiological profile and prognostic factors in patients with lung cancer. , 2016, Revista da Associacao Medica Brasileira.

[11]  E. Esteban,et al.  Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study. , 2015, Future oncology.

[12]  G. Rodgers,et al.  Diagnosis and treatment of cancer‐related anemia , 2014, American journal of hematology.

[13]  Hushan Yang,et al.  Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies – results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers , 2013, BMC Cancer.

[14]  P. Gascón,et al.  Management of lung cancer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS) , 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[15]  A. Rossi,et al.  Treatment of advanced non small cell lung cancer. , 2011, Journal of thoracic disease.

[16]  L. Seymour,et al.  Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience. , 2007, Lung cancer.

[17]  F. Hirsch,et al.  Targeting Anemia in Patients with Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  J. Jett,et al.  A prognostic model for advanced stage nonsmall cell lung cancer , 2006, Cancer.

[19]  K. Kiura,et al.  Serum hemoglobin level determined at the first presentation is a poor prognostic indicator in patients with lung cancer. , 2005, Internal medicine.

[20]  Dirk Schrijvers,et al.  The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. , 2004, European journal of cancer.

[21]  D. Cella,et al.  The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Li Zhang,et al.  Clinical practice guidelines on cancer-related anemia (2012-2013 Edition). , 2012, Chinese clinical oncology.

[23]  Luba Nalysnyk,et al.  Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. , 2009, Clinical therapeutics.